<DOC>
	<DOC>NCT01396213</DOC>
	<brief_summary>A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free diet.</brief_summary>
	<brief_title>A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease</brief_title>
	<detailed_description>This is a double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of three different doses (0.5, 1 and 2 mg TID) of Larazotide Acetate as an adjunct to gluten-free diet in the treatment of patients with celiac disease (CD). The diagnosis of CD must have been established by jejunal biopsy as well as serology at some point in time prior to entry into the study. Patients must have symptoms despite being on a gluten-free diet as defined by a celiac disease domain of the gastrointestinal symptoms rating scale equal to or more than 2.0.</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Inclusion Criteria (select criteria, not all inclusive): biopsy proven and serologyconfirmed celiac disease (at any point in time prior to study entry) written informed consent age between 1875 BMI between 18.540 symptoms despite being on a glutenfree diet (diarrhea, nausea, stomach pain, bloating) must have attempted a glutenfree diet for at least 12 months CeDGSRS score measurable serology Exclusion Criteria (select criteria, not allinclusive): Refractory celiac disease diagnosed with chronic active GI disease, such as irritable bowel syndrome, inflammatory bowel disease etc. severe complications of celiac diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>celiac disease</keyword>
	<keyword>gastrointestinal symptoms</keyword>
	<keyword>gluten-free diet</keyword>
	<keyword>patients with biopsy-proven celiac disease with symptoms</keyword>
</DOC>